Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, which convenes in Chicago from June 3-7, 2022. Tempus is presenting fourteen abstracts, including one oral presentation, two poster discussions, and eleven poster presentations. 

“The research we’re presenting at this year’s conference showcases the breadth and effectiveness of our offerings for oncologists, whether it is our RNA sequencing capabilities or our just-in-time clinical trial matching program,” said Dr. James L. Chen, Senior Vice President of Cancer Informatics at Tempus. “We’ve been fortunate enough to work with physicians across the country to advance research that can have a real impact in improving patient outcomes.”

The presented research showcases Tempus’ comprehensive collection of precision medicine solutions that are uniquely equipped to support physicians in optimizing each patient’s treatment. Tempus’ oral discussion and poster presentation highlights, include: 

• Oral Discussion: Operational Metrics for the ELAINE II study Combining a Traditional Approach with a Just-in-TIME Model
  • Session Date & Time: June 6, 2022, 3:00 – 6:00 PM CDT
  • Overview: This study demonstrates the success that Tempus’ TIME Trial Program had with Sermonix’s Elaine II trial for patients with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer. It found that TIME trial sites enrolled their first patient nearly four months faster than traditional sites, and the same sites contributed 44.8% of the patients that were enrolled in the study. Ultimately, the Elaine II trial enrolled all patients in eight months, while the anticipated enrollment duration was twelve to eighteen months

• Poster Title: #69 – Clinical whole transcriptome profiling improves the detection of clinically actionable fusions over DNA sequencing alone
  • Session Date & Time: June 5, 2022, 8:00 – 11:00 AM CDT
  • Overview: In the largest fusion analysis of its kind, Tempus reviewed a real-world dataset of 84,938 patient records for improvement in clinically actionable fusion detection due to the inclusion of RNA sequencing. The study found that RNA sequencing identified 29% more patients with clinically actionable fusions that were matched to biomarker linked therapies and that would have been missed by DNA sequencing alone.

• Poster Title: #9 – Dual tissue and plasma testing improves detection of actionable variants in patients with solid cancers
  • Session Date & Time: June 5, 2022, 8:00-11:00 AM & 4:30 – 6:00 PM CDT
  • Overview: This study found that 4 out of 10 patients had unique actionable variants linked to targeted therapies from doing both solid tumor and liquid biopsy testing that would have been missed by single modality testing alone. In the study, 42% of an overall cohort of 3,153 patients had clinically actionable variants detected through tissue-based comprehensive genomic profiling and/or liquid biopsy. Of these patients with clinically actionable variants, all linked to targeted therapies, 37% were uniquely identified through tissue testing only or by liquid biopsy only.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit https://tempus.co/3z8gjDf.